Zylö Therapeutics, a nanotechnology-based biopharmaceutical company dedicated to bringing innovative technologies to multiple facets of medicine, announced that preclinical data, utilizing Zylö’s patented hydrogel-derived Nanopods™ to deliver endocannabinoids for the treatment of cutaneous lupus in an established animal model, will be presented for the first time. 

Dr. Adam Friedman, Associate Professor of Dermatology at the George Washington School of Medicine and Health Sciences and co-inventor of the Nanopods™, will be directing session F003 ‘Treating Tumors and Inflammatory Skin Diseases with Immunomodulators and Biologics’ on Friday, February 16, 2018  9-11AM. During the session, he will present the lecture “The Potential of Cannabinoids for the Treatment of Inflammatory and Neoplastic Diseases of the Skin.” 

Dr. Friedman commented: “I will review the biology of the endocannabinoid system as it relates to the skin, present the available preclinical and clinical data on applications of cannabinoids for the treatment of inflammatory and neoplastic skin diseases, and present new data showing improved cutaneous delivery of cannabinoids through the skin utilizing nanotechnology and the robust impact on cutaneous lupus in a well-established animal model.”